Payment overview · 2025
General Payments
$449.00
25 reported records · 9 companies
Healthcare provider profile · identity verified
David Lawrence Moody, MD
Allopathic & Osteopathic Physicians|Family Medicine · CARTHAGE, MS · NPI 1346359197
Verified facts
What the public records show
CMS Open Payments records show David Lawrence Moody, MD received $449.00 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $119.69 | 26.7% | 7 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $103.22 | 23.0% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $70.01 | 15.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.19 | 9.8% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $38.83 | 8.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.07 | 4.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.85 | 4.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.87 | 4.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.27 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $449.00 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $103.22 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $70.01 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $62.98 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $56.71 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.19 | 3 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $38.83 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
180 | 36 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
222 | 49 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 16 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 725 | 115 |
| Atorvastatin Calcium | Atorvastatin Calcium | 691 | 131 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 666 | 90 |
| Furosemide | Furosemide | 608 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 548 | 73 |
| Omeprazole | Omeprazole | 498 | 112 |
| Eliquis | Apixaban | 407 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 385 | 89 |
| Potassium Chloride | Potassium Chloride | 376 | 81 |
| Meloxicam | Meloxicam | 340 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 323 | 67 |
| Trazodone Hcl | Trazodone Hcl | 315 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 274 | 43 |
| Alprazolam | Alprazolam | 262 | 33 |
| Memantine Hcl | Memantine Hcl | 256 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 237 | 52 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 233 | 57 |
| Lisinopril | Lisinopril | 230 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 224 | 25 |
| Synthroid | Levothyroxine Sodium | 222 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 51 |
| Carvedilol | Carvedilol | 216 | 39 |
| Baclofen | Baclofen | 215 | 57 |
| Losartan Potassium | Losartan Potassium | 211 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 210 | 26 |
| Donepezil Hcl | Donepezil Hcl | 207 | 36 |
| Montelukast Sodium | Montelukast Sodium | 206 | 36 |
| Linzess | Linaclotide | 180 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 171 | 25 |
| Azithromycin | Azithromycin | 168 | 108 |
| Metoprolol Tartrate | Metoprolol Tartrate | 168 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 165 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 157 | 24 |
| Tramadol Hcl | Tramadol Hcl | 145 | 29 |
| Sertraline Hcl | Sertraline Hcl | 142 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 138 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 136 | 27 |
| Famotidine | Famotidine | 133 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 129 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 124 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 119 | 18 |
| Metformin Hcl | Metformin Hcl | 119 | 31 |
| Promethazine Hcl | Promethazine Hcl | 117 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 113 | 14 |
| Pregabalin | Pregabalin | 111 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 109 | 77 |
| Myrbetriq | Mirabegron | 106 | 13 |
| Ozempic | Semaglutide | 105 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 104 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 102 | 54 |
| Mirtazapine | Mirtazapine | 101 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 98 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 22 |
| Allopurinol | Allopurinol | 94 | 21 |
| Ibuprofen | Ibuprofen | 94 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 94 | 15 |
| Levetiracetam | Levetiracetam | 92 | 11 |
| Spironolactone | Spironolactone | 91 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 71 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 26 |
| Jardiance | Empagliflozin | 84 | 14 |
| Meclizine Hcl | Meclizine Hcl | 84 | 31 |
| Fluconazole | Fluconazole | 83 | 35 |
| Clindamycin Hcl | Clindamycin Hcl | 81 | 46 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 80 | 48 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 80 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 12 |
| Simvastatin | Simvastatin | 77 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 74 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 19 |
| Mounjaro | Tirzepatide | 73 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 69 | 18 |
| Warfarin Sodium | Warfarin Sodium | 68 | 14 |
| Risperidone | Risperidone | 67 | 12 |
| Clonazepam | Clonazepam | 65 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 25 |
| Celecoxib | Celecoxib | 64 | 11 |
| Entresto | Sacubitril/Valsartan | 63 | suppressed |
| Atenolol | Atenolol | 62 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 61 | 19 |
| Trintellix | Vortioxetine Hydrobromide | 61 | 11 |
| Buspirone Hcl | Buspirone Hcl | 60 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 60 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 60 | suppressed |
| Prednisone | Prednisone | 60 | 44 |
| Levofloxacin | Levofloxacin | 59 | 55 |
| Lorazepam | Lorazepam | 59 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 58 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 57 | suppressed |
| Bupropion Xl | Bupropion Hcl | 56 | suppressed |
| Diazepam | Diazepam | 56 | suppressed |
| Ezetimibe | Ezetimibe | 56 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 56 | suppressed |
| Finasteride | Finasteride | 55 | 11 |
| Olanzapine | Olanzapine | 55 | suppressed |
| Digoxin | Digoxin | 53 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 14 |
| Aripiprazole | Aripiprazole | 50 | suppressed |
| Sucralfate | Sucralfate | 49 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 12 |
| Clonidine Hcl | Clonidine Hcl | 48 | 17 |
| Glipizide | Glipizide | 48 | suppressed |
| Nystatin | Nystatin | 48 | 14 |
| Oxcarbazepine | Oxcarbazepine | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 14 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 47 | 46 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Methylprednisolone | Methylprednisolone | 46 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | suppressed |
| Fentanyl | Fentanyl | 44 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 44 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Nifedipine Er | Nifedipine | 43 | suppressed |
| Temazepam | Temazepam | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Glipizide Er | Glipizide | 42 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Humalog | Insulin Lispro | 40 | suppressed |
| Irbesartan | Irbesartan | 40 | suppressed |
| Novolog | Insulin Aspart | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | 13 |
| Glimepiride | Glimepiride | 39 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 39 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Nabumetone | Nabumetone | 36 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Methocarbamol | Methocarbamol | 33 | 12 |
| Novolin R | Insulin Regular, Human | 33 | suppressed |
| Rybelsus | Semaglutide | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Latanoprost | Latanoprost | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 15 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 31 | suppressed |
| Lidocaine | Lidocaine | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 18 |
| Sodium Chloride | 0.9 % Sodium Chloride | 30 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 29 | suppressed |
| Carbamazepine Er | Carbamazepine | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Famotidine | Famotidine/Pf | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Krystexxa | Pegloticase | 25 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 25 | suppressed |
| Levemir | Insulin Detemir | 24 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 15 |
| Trulance | Plecanatide | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Glucagon Emergency Kit | Glucagon Hcl | 22 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Humulin R | Insulin Regular, Human | 21 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Scopolamine | Scopolamine | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Probenecid-Colchicine | Probenecid/Colchicine | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 15 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Alogliptin | Alogliptin Benzoate | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 12 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $449.00 · 25 records | AstraZeneca Pharmaceuticals LP | AREXVY, BREZTRI, CAPLYTA, FARXIGA, Kerendia, Ozempic, PURIFIED CORTROPHIN GEL, QUTENZA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error